Navigation Links
Novasys Medical Receives $18.95 Million in Second Tranche of Series D Financing
Date:7/21/2009

NEWARK, Calif., July 21 /PRNewswire/ -- Novasys Medical, Inc., developer of the Renessa(R) treatment for female stress urinary incontinence, announced today that it has received $18.95 million in the second tranche of its previously announced Series D preferred stock financing. The Company received the first tranche of the Series D round in May 2008, with lead investor Versant Ventures and new investors ThreeArch Partners and Skyline Ventures. All three participated in the second tranche, with existing investors Alloy Ventures, Delphi Ventures, GBS Venture Partners and Hercules Technology Growth Capital.

"In this challenging financing environment, we greatly value the continued support of our investors. They understand the tremendous opportunity the non-surgical Renessa treatment offers women," said Debra Reisenthel, President and CEO of Novasys Medical. "This financing will speed the process of securing reimbursement for the Renessa treatment. Since the first tranche of the Series D financing closed last May, we've enjoyed major progress with several key payers agreeing to cover the procedure. These payers include Aetna, plus regional Medicare carriers Noridian , First Coast and TrailBlazers, who cover 27 million lives. Additional payers are expected to join them in covering Renessa soon."

Beckie Robertson, Managing Director with Versant Ventures, said, "We're really pleased with the reimbursement progress Novasys has made with payers in the past year. We're confident this is a huge opportunity in an underserved market."

Female Stress Urinary Incontinence (SUI)

SUI is the involuntary leakage of urine associated with coughing, sneezing, laughing and recreational activities. It is caused by a variety of factors---most commonly childbirth---and often restricts the social, professional, and personal lives of an estimated 15 million women in the U.S. alone. With currently available surgical and non-surgical SUI therapies, many patients and physicians have concerns about safety, recovery, compliance and/or effectiveness. Experts estimate 80% of women with SUI thus do not seek treatment of any kind.

The FDA-cleared Renessa System includes a small probe which a physician passes through the natural opening of the urethra (transurethral). The probe gently heats the tissue in the bladder neck and upper urethra. The heat denatures the collagen in the tissue, and upon healing, the tissue becomes firmer and more resistant to leaks. The Renessa treatment can be performed in the convenience of a physician's office, or in an outpatient setting, using local anesthesia. There are no incisions, bandages or dressings required. Recovery is rapid and comfortable, with minimal post-procedure limitations. More than 350 urologists, urogynecologists and gynecologists have been trained and have performed the Renessa procedure in nearly 3,000 patients.

About Novasys Medical

Novasys Medical, Inc. is a privately held, venture-backed company which develops innovative therapies in women's health. The company's initial focus is the development and commercialization of the Renessa System, a proprietary, non-surgical approach to the treatment of female stress urinary incontinence (SUI).

For more information, please visit www.novasysmedical.com or call (510) 226-4060.


'/>"/>
SOURCE Novasys Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Aetna Now Covers Novasys Medicals Renessa(R) Treatment for Incontinence in Women
2. Owensboro Medical Health System Announces Results of Its Modified Dutch Auction Tender Offer
3. HealthCare Partners of Nevada and Fremont Medical Center Join Forces
4. All Allied Health Schools Helps Medical Coding Students Prepare for New Health Care World
5. Growth in African Medical Imaging Markets: Frost & Sullivan Examines the Potential
6. President Obama Holds Roundtable Discussion on Health Reform at Children's National Medical Center
7. Can pen and paper help make electronic medical records better?
8. ATS Medical Announces First Use of the New ATS CryoMaze 10-S Probe
9. Wake Forest Baptist Medical Center Names Chadwick CFO
10. One Healthcare Solution and MedBeyond Partner to Provide Optimum Solution for EMR and Medical Billing
11. MultiNational Underwriters Is Now HCC Medical Insurance Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named Herr the “Leader ... biomechatronics, technology that marries human physiology with electromechanics. He continues that work as Director ... Founder of BionX , a leader in the field of prosthetic devices. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore ... This is unfortunately true. But we toss the baby out with the bathwater when ... provides tips for identifying higher-quality studies and otherwise making better use of education policy ...
(Date:4/28/2016)... AZ (PRWEB) , ... April ... ... the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced a ... platform will provide efficient access to medical knowledge, educational resources, and a ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation ... Community Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with ... introducing an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services ...
(Date:4/28/2016)... , ... April 28, 2016 , ... Denise McCormick Baich had written poetry dating back ... poetry arrived again much like a tsunami and took on a more spiritual tone. The ... encouraged her to do more with it than just file it away. Friends would ask ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... New York , April 27, 2016 ... market report titled, "Skincare Devices Market - Global Industry ... 2023." According to the report, the global skincare devices ... and is anticipated to expand at a CAGR of ... Mn in 2023. Browse the full Skincare Devices ...
(Date:4/27/2016)... Research and Markets has ... Disposables Market 2016-2020"  report to their offering.  ... global anesthesia disposables market is set to ... the period 2016-2020.  Healthcare-acquired infections ... safety. Organizations like the CDC and Public ...
(Date:4/26/2016)... 2016 Diplomat Pharmacy, Inc. (NYSE: DPLO) is ... , Pharm D., to Vice President of Education and ... Hagerman will continue to lead and oversee Diplomat University, ... education and training to Diplomat employees and external professionals ... University also houses the quality assurance department, which focuses ...
Breaking Medicine Technology: